Artificial Intelligence & Machine Learning
,
Healthcare
,
Industry Specific
Pact Is Among Other Similar Biotech, AI Firm Collaborations to Speed Up Drug R&D

Merck has struck a multi-year deal with Google Cloud worth up to $1 billion to enhance the pharmaceutical and life sciences giant’s digital backbone “as an artificial intelligence-enabled enterprise.” The initiative includes deploying an agentic AI platform across all aspects of Merck’s operations including research and development, manufacturing, commercial and corporate functions.
See Also: Reduce Cloud Risk in Healthcare with Security by Default
The deal includes Google Cloud engineers “working alongside Merck teams” to deploy Google Cloud’s AI technologies, including Gemini Enterprise.
“Merck’s collaboration with Google Cloud represents the next phase of our AI journey,” said Dave Williams, chief information and digital officer of Merck. “AI agents and generative tools will help our teams around the world reimagine processes at scale and bring scientific breakthroughs to patients faster.”
“Human healthcare is a problem of profound data complexity,” a Merck spokesperson said in a statement to ISMG. “This partnership represents a fundamental shift in how technology supports the full pharmaceutical value chain – from early discovery and clinical development to manufacturing and commercial execution,” he said
The Merck and Google Cloud effort is the latest of several recent pacts between AI technology vendors and biotech companies worldwide.
Denmark-based pharmaceutical multinational Novo Nordisk disclosed on April 14 a strategic relationship with OpenAI aiming to help the drug maker bring “new and better treatment options to patients faster.”
Under that deal, Novo Nordisk will use AI to analyze complex datasets, identify promising drug candidates and shrink the time required “from research to patient.”
Novo Nordisk said the pact with OpenAI builds on the drug maker’s other ongoing AI initiatives, which include collaboration with other tech partners and research organizations.
Drug maker Eli Lilly forged a deal in late March valued up to $2.75 billion between Eli with Insilico Medicine. Eli Lilly will work with Insilico’s generative AI and automation tools for drug discovery collaboration. Pfizer also has a various deals with AI companies, including an agreement disclosed in January with applied AI research lab Boltz to build “state-of-the-art” biomolecular AI foundation models and generative workflows for Pfizer scientists to use in small-molecule and biologics design.
“Without a doubt, we are in the midst of a full-blown AI-arms race,” said Ian Tien, CEO of Mattermost, a sovereign collaboration platform provider.
“When a top-five pharma company commits $1 billion to AI infrastructure and a decade-long partnership, competitors don’t have the option to wait and see,” he said.
Given the costs involved – a failed trial can cost a billion dollars, while a successful drug can generate ten times that amount – any meaningful AI-driven speed advantage in R&D or regulatory timelines “translates directly to competitive survival,” Tien said.
What makes the Merck-Google deal significant is that this appears to be “far beyond a pilot,” said Aaron Estes, a vice president at security vendor Binary Defense and former cyber architect principal at Lockheed Martin.
“Once a major company signals that agentic AI can be pushed into core operations at this level, competitors are going to feel pressure to move faster.”
The use of AI tools in pharmaceutical and biotech initiatives is not without potential risks. Tempus AI, a healthcare AI firm that works with pharmaceutical makers and biotech is facing federal class action litigation alleging that it unlawfully sold genetic information of hundreds of thousands of patients (see: Health AI Firm Faces Lawsuits Over DNA Data Use, Disclosure).
The expansiveness of the Merck and Google Cloud agentic AI collaboration, from a cybersecurity standpoint, “means the real issue is no longer just model capability – it is enterprise control,” Estes said.
“The real risk in a Merck-Google type of arrangement is not just bad answers from the AI. It is giving these systems too much reach into important workflows before governance catches up,” he said.
Merck, in its statement to ISMG, said that in its partnership with Google, “we retain full ownership and control of our data, and all AI applications are deployed within governed environments that meet our global privacy, regulatory and cybersecurity standards.”
